4SC AG of Germany has reported that its lead cancer drug, resminostat, has met its primary endpoint in a Phase 2 trial of patients with refractory Hodgkin’s Lymphoma who had been heavily treated with other therapies prior to the trial.
Evotec AG of Hamburg said it has given an exclusive license to the Roche group for its inhibitor of monoamine oxidase type B (EVT302), which is being tested for treatment of Alzheimer’s disease.
Noxxon Pharma AG has started a Phase 1 study of an oligonucleotide-based drug to treat patients who suffer anaemia from chronic disease. The drug targets the peptide hormone, hepcidin, a regulator of iron metabolism.
A head-to-head study comparing AstraZeneca’s statin, Crestor (rosuvastatin), 40mg, with atorvastatin (Pfizer: Lipitor), 80 mg, failed to meet its primary endpoint in patients with coronary artery disease, according to AstraZeneca.
The Roche group has announced European approval of its cancer drug, Tarceva (erlotinib), as a first-line therapy for patients with non-small cell lung cancer whose tumours express mutations of the epidermal growth factor receptor (EGFR).
Ipsen SA has raised its sales target for sales of speciality pharmaceutical products for 2011 following a robust first-half year when total sales of medicines increased by 5.4% to €567 million, Speciality products were 65% of group consolidated sales.
Oxford BioMedica Plc said that recent, promising data from an ongoing Phase 1/2 study of its gene therapy, ProSavin, support the therapy’s potential as a treatment for the motor symptoms of Parkinson’s disease.
Ipsen SA has taken another step in the implementation of its speciality pharmaceutical strategy with plans to launch a new European commercial organisation to sell two still-to-be authorised products for people with haemophilia.
The US Food and Drug Administration has issued a ‘complete response letter’ to Novartis for its proposed treatment for gouty arthritis, canakinumab, requesting additional data on the drug’s benefit-risk profile in difficult-to-treat patients.
The US Food and Drug Administration has approved a new personalised medicine, Xalkori (crizotinib) together with a diagnostic, for the treatment of patients with late-stage non-small cell lung cancer who have abnormalities of the ALK gene.